Premium
Recent labeling changes for Vyvanse and Latuda
Publication year - 2017
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30209
Subject(s) - stimulant , food and drug administration , immediate release , drug labeling , citation , unit (ring theory) , psychology , medicine , psychiatry , advertising , pharmacology , drug , computer science , business , library science , mathematics education
Recently, the federal Food and Drug Administration approved a labeling change for the Vyvanse chewable tablet (lisdexamfetamine), a stimulant indicated to treat attention‐deficit hyperactivity disorder in children ages 6 to 17 years. The new labeling states: Vyvanse chewable tablets must be chewed thoroughly before swallowing. Vyvanse capsules can be substituted with Vyvanse chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet). This is a new formulation. The change was issued Jan. 28.